Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

8 November 2025

FDA clinical hold (Nov. 7): The U.S. Food and Drug Administration asked Tenaya to amend its MyPEAK‑1 Phase 1b/2a study of TN‑201 to standardize patient monitoring and immunosuppression management across sites. Tenaya says dosing will resume once changes are in place and does not expect data milestones to slip. Shares fell sharply after hours on the news. ^[1]
New clinical data unveiled today (Nov. 8): At AHA Scientific Sessions 2025, investigators reported interim safety and efficacy signals in six treated patients, with dose‑responsive increases in MyBP‑C protein and improvements in cardiac biomarkers and hypertrophy measures. Results were concurrently published in Cardiovascular Research. ^[2]
Independent coverage: Cleveland Clinic—an investigator site—said all six patients in this small early‑phase study “are no longer symptomatic,” while cautioning that more research is needed. ^[3]

What happened today (Nov. 8)

Tenaya Therapeutics (NASDAQ: TNYA) presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy (HCM). The late‑breaking presentation in New Orleans highlighted longer‑term follow‑up for the first‑dose cohort (3E13 vg/kg) and initial readouts at the higher dose (6E13 vg/kg), with a simultaneous publication in Cardiovascular Research. ^[4]

Cleveland Clinic, which led the podium talk, summarized the early experience: six adults treated across two dose cohorts were monitored for months to >1 year; the therapy reached heart cells, increased the target protein, and thinned the heart wall. The center noted that, at this checkpoint, all six patients were no longer symptomatic—but emphasized the dataset is small and early. ^[5]

The FDA hold: what it means and what it doesn’t

Late Friday (Nov. 7), Tenaya disclosed that the FDA placed MyPEAK‑1 on clinical hold to incorporate protocol amendments that standardize site practices for patient monitoring and for managing immunosuppression associated with gene therapy. According to the company’s Form 8‑K, the request followed proactive discussions about the program’s next steps and was based primarily on data already reviewed by the trial’s DSMB in summer 2025—data that supported enrollment expansion at both studied dose levels. Tenaya says no new meaningful safety events have occurred since that DSMB review. ^[6]

Reuters reported that TNYA fell more than 20% in after‑hours trading following the hold. The company said it is working with the FDA and does not expect the hold to delay planned data releases or the broader timeline for TN‑201. ^[7]

What the new TN‑201 data show (interim, early phase)

Highlights from Tenaya’s press release and talk at AHA 2025 include:

Safety/tolerability: Single‑dose TN‑201 at 3E13 and 6E13 vg/kg was generally well tolerated; no dose‑limiting toxicities were observed. Immunosuppression was tapered in all patients. Most frequent related events were reversible, asymptomatic transaminase elevations. No declines in LVEF, clinical myocarditis, or ventricular arrhythmias were reported. ^[8]
Pharmacodynamics:Transduction and mRNA expression increased with dose. In the higher‑dose cohort, an early patient showed a ~14% MyBP‑C increase at 12 weeks, alongside >2‑fold higher transduction vs. Cohort 1 averages. ^[9]
Biomarkers & imaging: In Cohort 1 (≥52 weeks), cardiac troponin I fell ~48%–74% toward normal; NT‑proBNP improved or stabilized in most patients. Measures of hypertrophy improved, including 21%–39% reductions in left ventricular posterior wall thickness (LVPWT) and 12%–22% reductions in LV mass index (LVMI) in a majority of Cohort 1 patients at 52 weeks. Functionally, all patients improved by ≥1 NYHA class by 26 weeks; all Cohort 1 patients are now NYHA Class I. ^[10]

Context: Cleveland Clinic characterized the early experience as “promising,” while underscoring the need for continued follow‑up and larger trials. ^[11]

Trial details:MyPEAK‑1 (ClinicalTrials.gov NCT05836259) is a multi‑center, open‑label, dose‑escalating study planned to enroll up to 24 symptomatic adults with MYBPC3‑associated HCM. ^[12]

Stock snapshot: TNYA

As of the latest trade (about 01:15 UTC, Nov. 8), TNYA was at $1.28. Note: U.S. markets are closed today (Saturday).

What’s next

Company call: Tenaya will host a webcast for analysts/investors on Monday, Nov. 10, 2025, at 8:00 a.m. ET to discuss today’s AHA data and the status of the trial. Details and slides will be posted on the company’s investor site. ^[13]
Regulatory path: The clinical hold centers on operational protocol standardization, not on newly identified safety signals, according to Tenaya’s SEC filing. The company intends to resume dosing after implementing the changes at sites. Timing will depend on FDA interactions and site readiness. ^[14]
Data cadence: Tenaya plans periodic updates as longer‑term follow‑up in Cohort 1 matures and early higher‑dose results accrue, which are expected to inform late‑stage development plans. ^[15]

Why this matters

MYBPC3‑associated HCM is a prevalent genetic subset of HCM; many patients have nonobstructive disease with no disease‑specific therapies. A one‑time gene replacement that raises MyBP‑C and reverses hypertrophy, if confirmed in larger trials, could redefine care—especially if benefits persist and safety remains manageable. Today’s signals are encouraging but preliminary; the FDA hold is a near‑term operational hurdle and a key watch item for investors and patients alike. ^[16]

Sources & further reading

Reuters: “US FDA places clinical hold on Tenaya gene therapy trial” (Nov. 7, 2025). ^[17]
Tenaya press release: “Presents Promising Interim Clinical Data from MyPEAK‑1” (Nov. 8, 2025). ^[18]
Cleveland Clinic newsroom: “Initial Results from First‑in‑Human Gene Therapy for HCM” (Nov. 8, 2025). ^[19]
SEC filing: Form 8‑K (Nov. 7, 2025) detailing the FDA requests and Tenaya’s plan. ^[20]
Trial record: NCT05836259 on ClinicalTrials.gov. ^[21]

Disclosure: This article is for information purposes only and does not constitute investment advice.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Scotiabank cuts TFPM price target; analysts divergent on Triple Flag Precious Metals outlook
November 8, 2025, 5:50 PM EST. Scotiabank trimmed Triple Flag Precious Metals (NYSE: TFPM) price objective from $35.00 to $34.00, with a sector perform rating and implied upside of about 19.3%. Analysts remain mixed: Canaccord Genuity moved to hold; Bank of America raised its target to $37 and reiterated a buy; Zacks Research boosted to strong-buy; CIBC reaffirmed an outperform; Wall Street Zen upgraded to buy. MarketBeat shows a consensus of Moderate Buy and a $30 target. TFPM traded near $28.50, with volume around 488k, and sits near its 50-day SMA vs the 200-day SMA. The stock carries a P/E around 28.2, a PEG of 0.88, solid liquidity, and a negative beta narrative. Latest quarterly results beat expectations on revenue of $93.5M and EPS of $0.24.
Eloro Resources (ELO:CA) AI-Generated Signals and Trading Plans - Nov 8, 2025
November 8, 2025, 5:48 PM EST. Eloro Resources Ltd. (ELO:CA) updates include AI-generated signals and structured trading plans. The notes show: buy near 1.13 with a target of 1.36 and a stop at 1.12, and a short near 1.36 aiming for 1.13 with a stop at 1.37. The data highlights updated AI signals and ratings across Near, Mid, and Long horizons, with Strong on all terms. The post references a time-stamped data check and a chart for ELO:CA. Investors should monitor the AI-driven outlook and the indicated levels as potential entry/exit points while considering risk management.
Scotiabank Increases Buenaventura Mining Target to $27.50, Sees ~22.8% Upside (BVN)
November 8, 2025, 5:18 PM EST. Scotiabank raised its price target on Buenaventura Mining (BVN) from $27.00 to $27.50, implying roughly a 22.8% upside from current levels. The firm preserves a sector perform rating. While BVN has drawn mixed notes from Zacks (hold-to-strong-buy), Weiss (buy), and Wall Street Zen, MarketBeat consolidates a Buy consensus with an average target of $27.50. BVN shares advanced about 3.2% to $22.40 on the session, with a volume of 592,015. The company trades around a P/E of 11.37, has a beta of 0.26, and a solid liquidity profile (current ratio 2.54, quick 2.31, debt-to-equity 0.23). Q3 earnings came in at $0.66 per share, topping estimates and supporting a positive earnings narrative.
Scotiabank Cuts AvePoint Price Target to $17; AVPT Slumps as Analysts Signal Mixed View
November 8, 2025, 5:16 PM EST. Scotiabank cut AvePoint's target price from $22.00 to $17.00 and kept a sector outperform stance, signaling about 40.7% upside from Friday's close. AVPT slid roughly 12.7% to $12.08 on heavy volume (4.24M vs. the 1.33M average). The stock trades near its 50-day MA ($15.13) and below the 200-day MA ($16.86). It has a 52-week range of $11.49-$20.25, a market cap near $2.56B, and a P/E of -241.55 with a beta of 1.40. Q3 results showed EPS $0.06 vs. $0.07 est; revenue $109.73M vs. $105.72M est. CFO James Caci sold 216,000 shares, cutting ownership by about 50%. MarketBeat shows a Moderate Buy on AVPT amid mixed analyst ratings.
Donaldson (DCI) Valuation Under Review After Steady Gains and Strong Long-Term Performance
November 8, 2025, 5:00 PM EST. Donaldson Company (DCI) has posted steady momentum, with a ~4% rise this month and a year-to-date return near 29%, contributing to a longer-term story of ~53% total shareholder return over three years and over 75% across five years. The stock closed at $86.86, above an $80 fair value narrative, prompting a closer look at the drivers behind valuation. Analysts point to global environmental regulations expanding demand for filtration across Industrial Solutions and Mobile Solutions, potentially lifting FY26 revenue and earnings. Yet risks include bioprocessing delays and heavy aftermarket reliance. The piece notes a bold margin shift and asks what single number could alter the outlook. Investors must decide if the recent rise fully prices in upside or if value remains compelling.